This could potentially be a suitable strategy for some ML-DS cases, as myeloid neoplasms with co-occurring mutations in EZH2 show increased dependency on RAS signalling, which renders tumour cells more sensitive to MEK inhibitors [182]. This evidence concerns the gene EZH2 and Dravet syndrome.